Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review
Journal of Brown Hospital Medicine · 22.06.2023 · 2 (3)
DOI: 10.56305/001c.81037 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Brown Hospital Medicine, online erschienen am 22.06.2023. Verfasst von Julia L Berkowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Rhode Island Hospital, Providence, RI, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The aim of this paper is to provide primary care providers and hospitalists with up-to-date guidance surrounding the management of anticoagulation and antiplatelet agents in periprocedural settings and when unexpected bleeding complications arise.
Methods
We searched PubMed, Cochrane CENTRAL, and Web of Science using applicable MeSH terms and keywords. No date limits or filters were applied. Articles cited by recent cardiovascular guidelines were also utilized.
Results
For direct oral anticoagulants (DOACs) and vitamin K agonists (VKAs), a patient’s risk for clot and procedural risk of bleeding should be assessed. Generally, patients considered at high risk for venous thromboembolism (VTE) should be bridged, patients at low risk should forgo bridging therapy, and patients in the intermediate range should be evaluated on a case-by-case basis. Emergent anticoagulation reversal treatment is available for both warfarin (i.e., prothrombin complex concentrate, phytonadione) and DOACs (i.e., idarucizumab for dabigatran reversal; andexanet alfa for apixaban and rivaroxaban reversal). DAPT does not need to be held for paracentesis or thoracentesis and is low risk for those needing urgent lumbar punctures. In patients with clinically significant bleeding, those with percutaneous coronary intervention (PCI) performed in the last three months should resume DAPT as soon as the patient is hemodynamically stable, while patients greater than three months out from PCI at high risk of bleed can be de-escalated to single antiplatelet therapy.
Conclusions
Appropriate management of anticoagulation and antiplatelet agents in the periprocedural setting and patients with active bleed remains critical in inpatient management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine Rhode Island Hospital, Providence, RI, USA.
- Warren Alpert Medical School at Brown University, Providence, RI, USA.
- Department of Medicine, Division of Cardiology Warren Alpert Medical School at Brown University, Providence, RI, USA.
- Lifespan Cardiovascular Institute, Providence, RI, USA.
ORCID-Profile: Julia L Berkowitz, Omar Hyder
Zitieren
APA
Berkowitz, J. L., Taylor, M. A., Lima, F. V., & Hyder, O. (2023). Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review. Journal of Brown Hospital Medicine, 2(3). https://doi.org/10.56305/001c.81037
Vancouver
Berkowitz JL, Taylor MA, Lima FV, Hyder O. Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review. Journal of Brown Hospital Medicine. 2023;2(3). doi:10.56305/001c.81037
BibTeX
@article{Berkowitz2023,
author = {Berkowitz, Julia L and Taylor, Matthew A and Lima, Fabio V and Hyder, Omar},
title = {Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review},
journal = {Journal of Brown Hospital Medicine},
year = {2023},
volume = {2},
number = {3},
doi = {10.56305/001c.81037}
}
EUVIMED